Abstract
The recent development of a novel class of insulin-sensitizing drugs, the thiazolidinediones (TZDs), represents a significant advance in antidiabetic therapy. One key mechanism by which these drugs exert their effects is by activation of the peroxisome proliferator activated receptor gamma (PPAR-gamma), a member of the nuclear receptor family. Evidence supporting this mechanism of action of the TZDs will be reviewed in this article. Recent data suggests that PPAR-gamma agonists might also have therapeutic potential in the treatment of inflammatory diseases and certain cancers.
MeSH terms
-
Animals
-
DNA-Binding Proteins / agonists
-
DNA-Binding Proteins / chemistry
-
DNA-Binding Proteins / therapeutic use*
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Humans
-
Inflammation / drug therapy
-
Ligands
-
Neoplasms / drug therapy
-
Receptors, Cytoplasmic and Nuclear / agonists*
-
Receptors, Cytoplasmic and Nuclear / chemistry
-
Thiazoles / chemistry
-
Thiazoles / therapeutic use*
-
Thiazolidinediones*
-
Transcription Factors / agonists*
-
Transcription Factors / chemistry
Substances
-
DNA-Binding Proteins
-
Ligands
-
Receptors, Cytoplasmic and Nuclear
-
Thiazoles
-
Thiazolidinediones
-
Transcription Factors
-
2,4-thiazolidinedione